Immuron ($40M MC) v. Innate Pharma ($850M MC)

This company Innate Pharmaceuticals (INNT) on NASDAQ, with only one compound in advanced stage (has a compound that is Phase III ready for Celiacs disease) trades at $850M market cap.  They also brag about an oral LPS-antagonist compound they have that is PRECLINICAL!  See below from Innate Pharmaceuticals website.  We have a Phase III ready compound in NASH that demonstrated statistically significant decreases in LPS, ALT, and AST and we trade at $40M market cap lol